Literature DB >> 12888073

Intumescent cataract after topical mitomycin-C for conjunctival malignant melanoma.

Stefan Sacu1, Nikolaus Ségur-Eltz, Reinhard Horvat, Julius R Lukas, Martin Zehetmayer.   

Abstract

PURPOSE: To present the clinical and histologic findings of a patient in whom intumescent cataract developed after successful topical mitomycin-C (MMC) chemotherapy for conjunctival melanoma originating from primary acquired conjunctival melanosis (PAM) with atypia.
DESIGN: Observational case report; follow-up at 30 months.
METHODS: In a patient with PAM and subsequent conjunctival melanoma that was successfully treated with topical MMC chemotherapy an intumescent cataract developed after two cycles of 0.04% MMC, each for 1 month.
RESULTS: After MMC chemotherapy pigmentation of the acquired melanosis vanished almost completely. Histopathology of the check-up specimen revealed local tumor control. Six weeks after the completion of the second cycle, an intumescent cataract developed. Cataract surgery was performed uneventfully. The patient was followed up for 30 months.
CONCLUSIONS: In selected cases, topical MMC chemotherapy is effective for treating conjunctival melanoma. Although severe complications are rare and usually transient, development of cataract may be observed. A prospective study should be initiated.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12888073     DOI: 10.1016/s0002-9394(03)00207-1

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  9 in total

1.  Topical mitomycin chemotherapy for malignant conjunctival and corneal neoplasia.

Authors:  P T Finger
Journal:  Br J Ophthalmol       Date:  2006-07       Impact factor: 4.638

Review 2.  Advances in the management of conjunctival melanoma.

Authors:  Gargi K Vora; Hakan Demirci; Brian Marr; Prithvi Mruthyunjaya
Journal:  Surv Ophthalmol       Date:  2016-06-16       Impact factor: 6.048

3.  Efficacy of low-dose topical mitomycin C treatment for primary acquired melanosis.

Authors:  Susan Hung; Tony Tsai; David Hwang; Joan O'Brien
Journal:  BMJ Case Rep       Date:  2009-06-01

4.  Complications of mitomycin C therapy in 100 eyes with ocular surface neoplasia.

Authors:  J J Khong; J Muecke
Journal:  Br J Ophthalmol       Date:  2006-05-03       Impact factor: 4.638

5.  Topical mitomycin chemotherapy for conjunctival malignant melanoma and primary acquired melanosis with atypia: 12 years' experience.

Authors:  Madhavi Kurli; Paul T Finger
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-06-07       Impact factor: 3.117

6.  Topical treatment options for conjunctival neoplasms.

Authors:  Jonathan W Kim; David H Abramson
Journal:  Clin Ophthalmol       Date:  2008-09

Review 7.  [Topical Mitomycin C as a therapy of conjunctival tumours].

Authors:  M Schallenberg; N Niederdräing; K-P Steuhl; D Meller
Journal:  Ophthalmologe       Date:  2008-08       Impact factor: 1.059

Review 8.  Mitomycin: clinical applications in ophthalmic practice.

Authors:  Lekha M Abraham; Dinesh Selva; Robert Casson; Igal Leibovitch
Journal:  Drugs       Date:  2006       Impact factor: 9.546

9.  The Use of TAT Peptide-Functionalized Graphene as a Highly Nuclear-Targeting Carrier System for Suppression of Choroidal Melanoma.

Authors:  Suyan Shan; Shujuan Jia; Tom Lawson; Lu Yan; Mimi Lin; Yong Liu
Journal:  Int J Mol Sci       Date:  2019-09-10       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.